Diagnosis and management of patients with malignant peritoneal mesothelioma

摘要: Malignant peritoneal mesothelioma (MPM) is a rare neoplastic condition that arises, usually diffusely, from the serosal membranes of abdominal cavity. MPM represents about 7% to 10% all diagnoses and this translates into approximately 800 cases per year in United States. The disease has variable tumor biology but progression, when it occurs, almost always within Although many patients can be successfully treated at initial presentation, fatal time. It afflicts men women equally median age presentation 50 years. diagnosis made diffuse malignant process cavity observed tissue sample reveals characteristic histopathology immunohistochemical profile mesothelioma. Initial staging via cross sectional imaging study abdomen pelvis making sure lower thorax also assessed. If burden distribution favorable then operative exploration, cytoreduction, hyperthermic intraperitoneal chemotherapy (HIPEC) are considered first line treatment selected patients. Systemic pemetrexed cisplatin (or gemcitabine) have modest response rates limited duration. Research advances with novel systemic or agents hold promise.